As the global ATMP market accelerates, success is increasingly determined by scalable manufacturing, regulatory agility and access to capital, not by science alone.
Sweden combines strong research capabilities, advanced process development, high-quality clinical data and regulatory credibility. This report outlines how Swedish ATMP players can capture global market opportunities and strengthen Sweden’s competitiveness in the next phase of advanced therapies.
Key takeaways from the report
- ATMP innovation is accelerating. Breakthroughs such as in vivo gene editing and next-generation CAR-T are expanding advanced therapies beyond oncology into chronic and solid tumour diseases.
- High costs challenge scalability. Complex manufacturing, particularly for patient-specific therapies, continues to limit commercial viability and requires new pricing and reimbursement models.
- Commercial setbacks are affecting investment. Early gene therapy challenges and strategic reprioritisation within the pharmaceutical industry have contributed to a more cautious investment climate.
- System readiness is critical. Scalable manufacturing, coordinated regulation and sustainable reimbursement are increasingly determining patient access and commercial success.
- Global competition is intensifying. The United States remains the leading ATMP market, while several countries in Asia are accelerating through strong investment and faster regulatory pathways.
- Sweden has strong global potential. Strengths in clinical research, process development, CMC and GMP manufacturing position Sweden’s ATMP ecosystem to capture growing global opportunities.
About the report Series
Executive Global Insight is Business Sweden’s report series offering Swedish business leaders in-depth analysis of the most critical developments shaping cross-border trade.
Each edition distills risks and opportunities into actionable insights, grounded in the expertise of Business Sweden’s advisors across more than 40 markets worldwide.
Subscribe to the report series here.
